Literature DB >> 25456130

Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.

Anindya Chatterjee1, Joydeep Ghosh2, Baskar Ramdas1, Raghuveer Singh Mali1, Holly Martin3, Michihiro Kobayashi1, Sasidhar Vemula1, Victor H Canela1, Emily R Waskow1, Valeria Visconte4, Ramon V Tiu4, Catherine C Smith5, Neil Shah5, Kevin D Bunting6, H Scott Boswell7, Yan Liu1, Rebecca J Chan3, Reuben Kapur8.   

Abstract

Oncogenic mutations of FLT3 and KIT receptors are associated with poor survival in patients with acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPNs), and currently available drugs are largely ineffective. Although Stat5 has been implicated in regulating several myeloid and lymphoid malignancies, how precisely Stat5 regulates leukemogenesis, including its nuclear translocation to induce gene transcription, is poorly understood. In leukemic cells, we show constitutive activation of focal adhesion kinase (FAK) whose inhibition represses leukemogenesis. Downstream of FAK, activation of Rac1 is regulated by RacGEF Tiam1, whose inhibition prolongs the survival of leukemic mice. Inhibition of the Rac1 effector PAK1 prolongs the survival of leukemic mice in part by inhibiting the nuclear translocation of Stat5. These results reveal a leukemic pathway involving FAK/Tiam1/Rac1/PAK1 and demonstrate an essential role for these signaling molecules in regulating the nuclear translocation of Stat5 in leukemogenesis.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25456130      PMCID: PMC4380442          DOI: 10.1016/j.celrep.2014.10.039

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  48 in total

1.  Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia.

Authors:  Anna Brady; Sarah Gibson; Lisa Rybicki; Eric Hsi; Yogen Saunthararajah; Mikkael A Sekeres; Ramon Tiu; Edward Copelan; Matt Kalaycio; Ronald Sobecks; Jennifer Bates; Anjali S Advani
Journal:  Eur J Haematol       Date:  2012-07-26       Impact factor: 2.997

2.  CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration.

Authors:  L Y Bourguignon; H Zhu; L Shao; Y W Chen
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

3.  Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL.

Authors:  Raghuveer Singh Mali; Baskar Ramdas; Peilin Ma; Jianjian Shi; Veerendra Munugalavadla; Emily Sims; Lei Wei; Sasidhar Vemula; Sarah C Nabinger; Charles B Goodwin; Rebecca J Chan; Fabiola Traina; Valeria Visconte; Ramon V Tiu; Timothy A Lewis; Andrew M Stern; Qiang Wen; John D Crispino; H Scott Boswell; Reuben Kapur
Journal:  Cancer Cell       Date:  2011-09-13       Impact factor: 31.743

4.  Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

Authors:  Chunaram Choudhary; Christian Brandts; Joachim Schwable; Lara Tickenbrock; Bülent Sargin; Andrea Ueker; Frank-D Böhmer; Wolfgang E Berdel; Carsten Müller-Tidow; Hubert Serve
Journal:  Blood       Date:  2007-03-13       Impact factor: 22.113

5.  Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.

Authors:  Hitoshi Kiyoi; Ryuzo Ohno; Ryuzo Ueda; Hidehiko Saito; Tomoki Naoe
Journal:  Oncogene       Date:  2002-04-11       Impact factor: 9.867

6.  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.

Authors:  Vita M Golubovskaya; Carl Nyberg; Min Zheng; Frederick Kweh; Andrew Magis; David Ostrov; William G Cance
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

7.  Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.

Authors:  Christian Baumgartner; Sabine Cerny-Reiterer; Karoline Sonneck; Matthias Mayerhofer; Karoline V Gleixner; Richard Fritz; Marc Kerenyi; Cedric Boudot; Fabrice Gouilleux; Jan-Wilhelm Kornfeld; Christian Sillaber; Richard Moriggl; Peter Valent
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

8.  PAK signaling in cancer.

Authors:  Diana Zi Ye; Jeffrey Field
Journal:  Cell Logist       Date:  2012-04-01

9.  Rac1 signalling modulates a STAT5/BCL-6 transcriptional switch on cell-cycle-associated target gene promoters.

Authors:  Patrícia Barros; Eric W-F Lam; Peter Jordan; Paulo Matos
Journal:  Nucleic Acids Res       Date:  2012-06-20       Impact factor: 16.971

10.  Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.

Authors:  Fabiola Traina; Valeria Visconte; Anna M Jankowska; Hideki Makishima; Christine L O'Keefe; Paul Elson; Yingchun Han; Fred H Hsieh; Mikkael A Sekeres; Raghuveer Singh Mali; Matt Kalaycio; Alan E Lichtin; Anjali S Advani; Hien K Duong; Edward Copelan; Reuben Kapur; Sara T Olalla Saad; Jaroslaw P Maciejewski; Ramon V Tiu
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

View more
  28 in total

1.  PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Ashley Pandolfi; Robert F Stanley; Yiting Yu; Boris Bartholdy; Gopichand Pendurti; Kira Gritsman; Jacqueline Boultwood; Jonathan Chernoff; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2015-07-13       Impact factor: 22.113

Review 2.  Signaling coupled epigenomic regulation of gene expression.

Authors:  R Kumar; S Deivendran; T R Santhoshkumar; M R Pillai
Journal:  Oncogene       Date:  2017-06-26       Impact factor: 9.867

3.  Pharmacological inhibition of aberrant transcription factor complexes in inversion 16 acute myeloid leukemia.

Authors:  Sandeep Potluri; Daniel Coleman; Constanze Bonifer
Journal:  Stem Cell Investig       Date:  2018-09-30

Review 4.  Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases.

Authors:  Rakesh Kumar; Aswathy Mary Paul; Ravikumar Amjesh; Bijesh George; M Radhakrishna Pillai
Journal:  Cancer Metastasis Rev       Date:  2020-08-21       Impact factor: 9.264

5.  DNA damage on the DOCK in FLT3-ITD-driven acute myeloid leukemia.

Authors:  Ruchi Pandey; Reuben Kapur
Journal:  Haematologica       Date:  2019-12       Impact factor: 9.941

6.  Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.

Authors:  Xiangmeng Wang; Po Yee Mak; Hong Mu; Wenjing Tao; Arvind Rao; Ravikumar Visweswaran; Vivian Ruvolo; Jonathan A Pachter; David T Weaver; Michael Andreeff; Bing Xu; Bing Z Carter
Journal:  Mol Cancer Ther       Date:  2020-05-13       Impact factor: 6.261

7.  Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.

Authors:  Ina-Katrin Siekmann; Kevin Dierck; Sebastian Prall; Marianne Klokow; Julia Strauss; Sophia Buhs; Antonina Wrzeszcz; Michael Bockmayr; Florian Beck; Magdalena Trochimiuk; Kristina Gottschling; Victoria Martens; Melissa Khosh-Naucke; Helwe Gerull; Jürgen Müller; Lena Behrmann; Martin Blohm; René P Zahedi; Irmela Jeremias; Albert Sickmann; Peter Nollau; Martin A Horstmann
Journal:  Blood Adv       Date:  2018-10-09

8.  Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.

Authors:  Oliver M Dovey; Jonathan L Cooper; Annalisa Mupo; Carolyn S Grove; Claire Lynn; Nathalie Conte; Robert M Andrews; Suruchi Pacharne; Konstantinos Tzelepis; M S Vijayabaskar; Paul Green; Roland Rad; Mark Arends; Penny Wright; Kosuke Yusa; Allan Bradley; Ignacio Varela; George S Vassiliou
Journal:  Blood       Date:  2017-08-23       Impact factor: 22.113

Review 9.  p21-Activated kinases as promising therapeutic targets in hematological malignancies.

Authors:  Andrew Wu; Xiaoyan Jiang
Journal:  Leukemia       Date:  2021-10-25       Impact factor: 11.528

10.  Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.

Authors:  Sabrina Kraus; Martin K Kortüm; Andoni Garitano-Trojaola; Ana Sancho; Ralph Götz; Patrick Eiring; Susanne Walz; Hardikkumar Jetani; Jesus Gil-Pulido; Matteo Claudio Da Via; Eva Teufel; Nadine Rhodes; Larissa Haertle; Estibaliz Arellano-Viera; Raoul Tibes; Andreas Rosenwald; Leo Rasche; Michael Hudecek; Markus Sauer; Jürgen Groll; Hermann Einsele
Journal:  Commun Biol       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.